As of 2026-03-23, the Relative Valuation of Terns Pharmaceuticals Inc (TERN) is (16.54) USD. This relative valuation is based on P/E multiples. With the latest stock price at 48.44 USD, the upside of Terns Pharmaceuticals Inc based on Relative Valuation is -134.1%.
The range of the Relative Valuation is (15.97) - (17.34) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.0x - 20.0x | 19.0x |
| Forward P/E multiples | 16.6x - 19.5x | 18.2x |
| Fair Price | (15.97) - (17.34) | (16.54) |
| Upside | -133.0% - -135.8% | -134.1% |
| Date | P/E |
| 2026-03-17 | -52.26 |
| 2026-03-16 | -51.81 |
| 2026-03-13 | -52.32 |
| 2026-03-12 | -49.75 |
| 2026-03-11 | -52.61 |
| 2026-03-10 | -50.93 |
| 2026-03-09 | -49.81 |
| 2026-03-06 | -48.15 |
| 2026-03-05 | -47.23 |
| 2026-03-04 | -47.83 |
| 2026-03-03 | -46.68 |
| 2026-03-02 | -47.27 |
| 2026-02-27 | -47.37 |
| 2026-02-26 | -46.02 |
| 2026-02-25 | -46.54 |
| 2026-02-24 | -46.61 |
| 2026-02-23 | -45.95 |
| 2026-02-20 | -44.12 |
| 2026-02-19 | -44.36 |
| 2026-02-18 | -44.25 |
| 2026-02-17 | -44.51 |
| 2026-02-13 | -42.50 |
| 2026-02-12 | -42.45 |
| 2026-02-11 | -43.45 |
| 2026-02-10 | -42.95 |
| 2026-02-09 | -42.71 |
| 2026-02-06 | -42.48 |
| 2026-02-05 | -39.74 |
| 2026-02-04 | -40.55 |
| 2026-02-03 | -43.32 |
| 2026-02-02 | -41.41 |
| 2026-01-30 | -38.91 |
| 2026-01-29 | -38.46 |
| 2026-01-28 | -38.53 |
| 2026-01-27 | -39.46 |
| 2026-01-26 | -38.74 |
| 2026-01-23 | -38.61 |
| 2026-01-22 | -40.45 |
| 2026-01-21 | -41.23 |
| 2026-01-20 | -41.14 |
| 2026-01-16 | -41.16 |
| 2026-01-15 | -41.59 |
| 2026-01-14 | -41.81 |
| 2026-01-13 | -38.74 |
| 2026-01-12 | -38.36 |
| 2026-01-09 | -39.90 |
| 2026-01-08 | -42.48 |
| 2026-01-07 | -44.98 |
| 2026-01-06 | -43.09 |
| 2026-01-05 | -44.07 |